Home » Life Tech, VelaDx Ink Sequencing-based Dx Deal

Life Tech, VelaDx Ink Sequencing-based Dx Deal

Oct 09, 2012
|
staff reporter

NEW YORK (GenomeWeb News) – Life Technologies today said that it has signed a licensing and supply deal with VelaDx providing the Singapore-based firm rights to develop clinical diagnostic tests on Life Tech's Ion Personal Genome Machine platform.

Under the terms of the deal VelaDx will seek regulatory approvals from global authorities to sell clinical tests for oncology and infectious disease applications. Further terms of the alliance were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

What's Popular?

In Clinical Sequencing

  1. Families Declining Enrollment in BabySeq Cite Lack of Interest in Research, Logistical Challenges

  2. Survey Finds QC Best Practices in Clinical Genomics Still Developing

  3. Bristol-Myers Squibb to Use Natera's Cell-Free DNA Assay in Immunotherapy Study

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.